 Christina Coughlan
Concepts (363)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 11 | 2026 | 614 | 2.330 |
Why?
| | Extracellular Vesicles | 9 | 2025 | 160 | 2.080 |
Why?
| | Exosomes | 3 | 2023 | 104 | 0.810 |
Why?
| | Astrocytes | 4 | 2022 | 218 | 0.790 |
Why?
| | White Matter | 2 | 2023 | 150 | 0.750 |
Why?
| | Gliosis | 2 | 2023 | 29 | 0.730 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2022 | 162 | 0.720 |
Why?
| | Glial Fibrillary Acidic Protein | 2 | 2025 | 111 | 0.710 |
Why?
| | Sialyltransferases | 8 | 1999 | 13 | 0.700 |
Why?
| | Amyloid beta-Protein Precursor | 5 | 2022 | 64 | 0.670 |
Why?
| | Healthy Aging | 1 | 2021 | 37 | 0.650 |
Why?
| | Ultracentrifugation | 1 | 2020 | 50 | 0.650 |
Why?
| | Memory, Episodic | 1 | 2021 | 54 | 0.650 |
Why?
| | Neurons | 8 | 2026 | 1632 | 0.570 |
Why?
| | Amyloid beta-Peptides | 6 | 2026 | 236 | 0.550 |
Why?
| | Saccharomyces cerevisiae | 5 | 2022 | 568 | 0.540 |
Why?
| | Proteomics | 4 | 2026 | 1192 | 0.500 |
Why?
| | Peptide Fragments | 3 | 2022 | 706 | 0.460 |
Why?
| | Nanoparticles | 1 | 2020 | 514 | 0.420 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 451 | 0.420 |
Why?
| | Dexamethasone | 7 | 1999 | 373 | 0.390 |
Why?
| | Brain Ischemia | 2 | 2025 | 355 | 0.320 |
Why?
| | Herpes Zoster | 3 | 2024 | 315 | 0.320 |
Why?
| | Islet Amyloid Polypeptide | 2 | 2021 | 48 | 0.320 |
Why?
| | Down Syndrome | 4 | 2022 | 523 | 0.310 |
Why?
| | Sialoglycoproteins | 3 | 1997 | 158 | 0.280 |
Why?
| | Protein Folding | 3 | 2005 | 283 | 0.270 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2025 | 152 | 0.260 |
Why?
| | Aging | 4 | 2026 | 1968 | 0.250 |
Why?
| | Interleukin-6 | 3 | 2026 | 791 | 0.250 |
Why?
| | Biomarkers | 9 | 2026 | 4248 | 0.250 |
Why?
| | Oligoclonal Bands | 1 | 2026 | 26 | 0.240 |
Why?
| | Herpesvirus 3, Human | 3 | 2024 | 333 | 0.240 |
Why?
| | Neuroblastoma | 3 | 1999 | 168 | 0.230 |
Why?
| | Aged, 80 and over | 9 | 2026 | 8130 | 0.230 |
Why?
| | Stroke | 3 | 2023 | 1219 | 0.230 |
Why?
| | Proteome | 2 | 2024 | 510 | 0.230 |
Why?
| | Plasma | 2 | 2024 | 227 | 0.230 |
Why?
| | Sodium Bicarbonate | 1 | 2025 | 46 | 0.220 |
Why?
| | Humans | 40 | 2026 | 143817 | 0.220 |
Why?
| | Protein Conformation | 2 | 2005 | 933 | 0.220 |
Why?
| | Tetraspanin 28 | 1 | 2024 | 6 | 0.220 |
Why?
| | Intra-Abdominal Fat | 1 | 2025 | 101 | 0.220 |
Why?
| | Chordoma | 1 | 2024 | 17 | 0.220 |
Why?
| | DNA Transposable Elements | 1 | 2025 | 121 | 0.210 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2024 | 681 | 0.210 |
Why?
| | alpha-Synuclein | 1 | 2024 | 46 | 0.210 |
Why?
| | Acidosis | 1 | 2025 | 105 | 0.210 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2025 | 176 | 0.210 |
Why?
| | Amyloidogenic Proteins | 1 | 2024 | 16 | 0.210 |
Why?
| | Mitochondria | 2 | 2025 | 983 | 0.210 |
Why?
| | Aprotinin | 1 | 2004 | 11 | 0.210 |
Why?
| | Varicella Zoster Virus Infection | 2 | 2024 | 24 | 0.210 |
Why?
| | Vacuoles | 1 | 2004 | 38 | 0.210 |
Why?
| | Osteoblasts | 1 | 2024 | 144 | 0.210 |
Why?
| | Central Nervous System | 1 | 2026 | 272 | 0.200 |
Why?
| | Glucocorticoids | 3 | 1999 | 539 | 0.200 |
Why?
| | Recombinant Proteins | 2 | 2007 | 1355 | 0.200 |
Why?
| | Carcinogenesis | 1 | 2025 | 231 | 0.200 |
Why?
| | Animals | 24 | 2025 | 38140 | 0.200 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 738 | 0.200 |
Why?
| | Neurodegenerative Diseases | 1 | 2005 | 141 | 0.190 |
Why?
| | Bleomycin | 1 | 2024 | 246 | 0.190 |
Why?
| | Cerebrovascular Circulation | 1 | 2025 | 272 | 0.190 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 224 | 0.190 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 97 | 0.180 |
Why?
| | Colon | 1 | 2025 | 303 | 0.180 |
Why?
| | Apolipoprotein E4 | 1 | 2022 | 39 | 0.180 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 69 | 0.180 |
Why?
| | Disease | 1 | 2003 | 98 | 0.180 |
Why?
| | Protein Processing, Post-Translational | 4 | 2011 | 477 | 0.180 |
Why?
| | Fatty Acids | 1 | 2025 | 450 | 0.180 |
Why?
| | Cognition | 3 | 2025 | 1252 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2025 | 307 | 0.180 |
Why?
| | Obesity | 2 | 2025 | 3073 | 0.180 |
Why?
| | Aged | 13 | 2026 | 25616 | 0.180 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2024 | 644 | 0.180 |
Why?
| | Immunoglobulin G | 1 | 2026 | 899 | 0.170 |
Why?
| | Endoplasmic Reticulum | 1 | 2004 | 266 | 0.170 |
Why?
| | Retinal Drusen | 1 | 2021 | 31 | 0.170 |
Why?
| | Peptides | 2 | 2024 | 986 | 0.170 |
Why?
| | Virion | 1 | 2022 | 115 | 0.170 |
Why?
| | Retinal Pigment Epithelium | 1 | 2021 | 78 | 0.170 |
Why?
| | Aldosterone | 4 | 1999 | 43 | 0.170 |
Why?
| | Arteritis | 1 | 2021 | 25 | 0.170 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2022 | 77 | 0.170 |
Why?
| | Chemical Precipitation | 1 | 2020 | 39 | 0.160 |
Why?
| | Cell Polarity | 1 | 2021 | 139 | 0.160 |
Why?
| | Health Status | 1 | 2026 | 821 | 0.160 |
Why?
| | Myelitis | 1 | 2022 | 106 | 0.160 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2021 | 147 | 0.160 |
Why?
| | Stem Cells | 1 | 2025 | 622 | 0.160 |
Why?
| | Adipose Tissue | 1 | 2025 | 656 | 0.160 |
Why?
| | Enterovirus D, Human | 1 | 2022 | 87 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 684 | 0.160 |
Why?
| | Amyloid | 1 | 2021 | 95 | 0.160 |
Why?
| | Multiple Sclerosis | 1 | 2026 | 482 | 0.160 |
Why?
| | Receptors, Chemokine | 1 | 2000 | 48 | 0.160 |
Why?
| | Cell Movement | 1 | 2024 | 973 | 0.160 |
Why?
| | Neuromuscular Diseases | 1 | 2022 | 144 | 0.150 |
Why?
| | Inflammation | 3 | 2026 | 2893 | 0.150 |
Why?
| | Chemokine CCL2 | 1 | 2000 | 115 | 0.150 |
Why?
| | Macular Degeneration | 1 | 2021 | 190 | 0.150 |
Why?
| | Adrenal Cortex Hormones | 3 | 1999 | 500 | 0.150 |
Why?
| | Enterovirus Infections | 1 | 2022 | 174 | 0.150 |
Why?
| | Wnt-5a Protein | 1 | 2018 | 25 | 0.150 |
Why?
| | Middle Aged | 12 | 2026 | 35629 | 0.140 |
Why?
| | Fibroblasts | 1 | 2024 | 1035 | 0.140 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2025 | 647 | 0.140 |
Why?
| | Signal Transduction | 4 | 2021 | 5241 | 0.140 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3609 | 0.140 |
Why?
| | Male | 17 | 2026 | 71568 | 0.140 |
Why?
| | Frontotemporal Lobar Degeneration | 1 | 2017 | 19 | 0.130 |
Why?
| | Kidney | 2 | 2015 | 1483 | 0.130 |
Why?
| | Cell Communication | 2 | 2000 | 325 | 0.130 |
Why?
| | N-Acetylneuraminic Acid | 2 | 1999 | 16 | 0.130 |
Why?
| | Proteostasis Deficiencies | 1 | 2017 | 5 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2025 | 848 | 0.130 |
Why?
| | Melanoma | 1 | 2024 | 806 | 0.130 |
Why?
| | Aneuploidy | 1 | 2017 | 89 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2025 | 927 | 0.130 |
Why?
| | tau Proteins | 1 | 2017 | 101 | 0.130 |
Why?
| | Tumor Cells, Cultured | 5 | 2000 | 944 | 0.130 |
Why?
| | Female | 16 | 2026 | 77569 | 0.130 |
Why?
| | Glycosylation | 4 | 2026 | 173 | 0.120 |
Why?
| | Trisomy | 1 | 2017 | 78 | 0.120 |
Why?
| | Brain Chemistry | 1 | 1996 | 116 | 0.120 |
Why?
| | Proteins | 1 | 2021 | 1023 | 0.110 |
Why?
| | Isoenzymes | 1 | 1996 | 299 | 0.110 |
Why?
| | Endosomal Sorting Complexes Required for Transport | 2 | 2025 | 46 | 0.110 |
Why?
| | Carcinoma, Hepatocellular | 2 | 1997 | 370 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2005 | 1118 | 0.110 |
Why?
| | Rats | 8 | 2025 | 5609 | 0.110 |
Why?
| | Apoptosis | 3 | 2025 | 2446 | 0.110 |
Why?
| | Models, Biological | 1 | 2003 | 1833 | 0.110 |
Why?
| | Neurofilament Proteins | 2 | 2025 | 64 | 0.110 |
Why?
| | Molecular Sequence Data | 5 | 2015 | 2914 | 0.100 |
Why?
| | Brain | 4 | 2023 | 2901 | 0.100 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4553 | 0.100 |
Why?
| | Mice | 10 | 2025 | 18421 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2015 | 255 | 0.100 |
Why?
| | Oxidative Stress | 2 | 2021 | 1377 | 0.100 |
Why?
| | Adult | 7 | 2026 | 40128 | 0.090 |
Why?
| | Membrane Proteins | 3 | 2024 | 1182 | 0.090 |
Why?
| | Enzyme Induction | 3 | 1997 | 87 | 0.090 |
Why?
| | Nerve Tissue Proteins | 1 | 1996 | 600 | 0.090 |
Why?
| | Amino Acid Sequence | 3 | 2015 | 2148 | 0.090 |
Why?
| | Transcription Factor AP-2 | 1 | 2011 | 82 | 0.090 |
Why?
| | Glioma | 1 | 1995 | 424 | 0.080 |
Why?
| | Parkinson Disease | 1 | 2017 | 595 | 0.080 |
Why?
| | Ethanol | 1 | 2015 | 626 | 0.080 |
Why?
| | Membrane Transport Proteins | 1 | 2011 | 154 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2025 | 6032 | 0.080 |
Why?
| | Adrenalectomy | 4 | 1999 | 71 | 0.080 |
Why?
| | Cells, Cultured | 4 | 2021 | 4172 | 0.080 |
Why?
| | Receptors, Nicotinic | 1 | 2011 | 326 | 0.070 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1174 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2590 | 0.070 |
Why?
| | Palliative Care | 1 | 2017 | 982 | 0.070 |
Why?
| | Caregivers | 1 | 2017 | 1025 | 0.070 |
Why?
| | Alcoholism | 1 | 2015 | 814 | 0.070 |
Why?
| | DNA-Binding Proteins | 2 | 2025 | 1493 | 0.070 |
Why?
| | Schizophrenia | 1 | 2011 | 430 | 0.070 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2011 | 406 | 0.060 |
Why?
| | Transcription Factors | 2 | 2025 | 1735 | 0.060 |
Why?
| | Liver | 1 | 1996 | 1846 | 0.060 |
Why?
| | Drug Stability | 1 | 2007 | 165 | 0.060 |
Why?
| | Chemokine CXCL5 | 1 | 2026 | 19 | 0.060 |
Why?
| | DNA Primers | 1 | 2007 | 516 | 0.060 |
Why?
| | Chemokine CXCL9 | 1 | 2026 | 38 | 0.060 |
Why?
| | Golgi Apparatus | 2 | 2004 | 102 | 0.060 |
Why?
| | Polysaccharides | 2 | 2004 | 89 | 0.060 |
Why?
| | Mutation | 4 | 2017 | 4106 | 0.060 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 59 | 0.060 |
Why?
| | Middle Cerebral Artery | 1 | 2025 | 55 | 0.060 |
Why?
| | Protein Aggregates | 1 | 2026 | 84 | 0.060 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2025 | 46 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2024 | 382 | 0.060 |
Why?
| | Cytokines | 2 | 2024 | 2093 | 0.060 |
Why?
| | DNA Methylation | 2 | 2025 | 673 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2023 | 3614 | 0.050 |
Why?
| | Calnexin | 1 | 2004 | 3 | 0.050 |
Why?
| | Centrifugation, Density Gradient | 1 | 2004 | 40 | 0.050 |
Why?
| | Cycloheximide | 1 | 2004 | 47 | 0.050 |
Why?
| | Concanavalin A | 1 | 2004 | 71 | 0.050 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2004 | 46 | 0.050 |
Why?
| | Kinetics | 2 | 1998 | 1622 | 0.050 |
Why?
| | Precipitin Tests | 1 | 2004 | 95 | 0.050 |
Why?
| | Cell Death | 1 | 2025 | 387 | 0.050 |
Why?
| | Mass Spectrometry | 1 | 2007 | 747 | 0.050 |
Why?
| | Virus Activation | 1 | 2024 | 92 | 0.050 |
Why?
| | Multienzyme Complexes | 1 | 2004 | 64 | 0.050 |
Why?
| | Fluorescent Dyes | 1 | 2025 | 327 | 0.050 |
Why?
| | Cysteine Endopeptidases | 1 | 2004 | 74 | 0.050 |
Why?
| | Base Sequence | 1 | 2007 | 2186 | 0.050 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2004 | 49 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2023 | 26 | 0.050 |
Why?
| | Disulfides | 1 | 2004 | 99 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 342 | 0.050 |
Why?
| | Time Factors | 2 | 2025 | 7068 | 0.050 |
Why?
| | Sensory Receptor Cells | 1 | 2024 | 101 | 0.050 |
Why?
| | Sucrose | 1 | 2004 | 112 | 0.050 |
Why?
| | Diet, High-Fat | 1 | 2025 | 262 | 0.050 |
Why?
| | Hippocampus | 2 | 2022 | 968 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2003 | 70 | 0.050 |
Why?
| | Fungal Proteins | 1 | 2004 | 145 | 0.050 |
Why?
| | Carbohydrate Sequence | 3 | 1999 | 29 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 50 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 74 | 0.050 |
Why?
| | beta Catenin | 1 | 2025 | 253 | 0.050 |
Why?
| | Plasmids | 1 | 2004 | 376 | 0.050 |
Why?
| | Imipramine | 1 | 2022 | 11 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2026 | 791 | 0.050 |
Why?
| | Growth Disorders | 1 | 2022 | 85 | 0.050 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 212 | 0.050 |
Why?
| | Chemokines | 1 | 2003 | 224 | 0.050 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2022 | 69 | 0.050 |
Why?
| | Densitometry | 1 | 2022 | 38 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2620 | 0.050 |
Why?
| | Retinal Ganglion Cells | 1 | 2003 | 121 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 155 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2024 | 481 | 0.040 |
Why?
| | Virus Internalization | 1 | 2022 | 66 | 0.040 |
Why?
| | Polymerization | 1 | 2022 | 131 | 0.040 |
Why?
| | Viral Proteins | 1 | 2024 | 365 | 0.040 |
Why?
| | Protein Structure, Tertiary | 1 | 2004 | 857 | 0.040 |
Why?
| | Catalysis | 1 | 2022 | 326 | 0.040 |
Why?
| | Cattle | 1 | 2004 | 1004 | 0.040 |
Why?
| | Lectins | 2 | 1998 | 44 | 0.040 |
Why?
| | Chromatin | 1 | 2025 | 554 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2025 | 3120 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2025 | 1096 | 0.040 |
Why?
| | Interneurons | 1 | 2022 | 127 | 0.040 |
Why?
| | Receptors, HIV | 1 | 2000 | 24 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2023 | 238 | 0.040 |
Why?
| | Neuroimaging | 1 | 2023 | 286 | 0.040 |
Why?
| | Immune System | 1 | 2022 | 182 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2021 | 278 | 0.040 |
Why?
| | Retina | 1 | 2003 | 321 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2017 | 0.040 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 320 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 1984 | 0.040 |
Why?
| | Teratocarcinoma | 1 | 2000 | 2 | 0.040 |
Why?
| | Receptors, Dopamine D2 | 1 | 2000 | 92 | 0.040 |
Why?
| | Organoids | 1 | 2021 | 135 | 0.040 |
Why?
| | Intracellular Space | 1 | 2020 | 67 | 0.040 |
Why?
| | Phagocytosis | 1 | 2021 | 297 | 0.040 |
Why?
| | Acyclovir | 1 | 2020 | 96 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1851 | 0.040 |
Why?
| | Extracellular Space | 1 | 2020 | 132 | 0.040 |
Why?
| | Phytohemagglutinins | 1 | 1999 | 29 | 0.040 |
Why?
| | Viral Envelope Proteins | 1 | 2020 | 99 | 0.040 |
Why?
| | Cerebral Palsy | 1 | 2021 | 127 | 0.040 |
Why?
| | Cell Line | 2 | 2022 | 2906 | 0.040 |
Why?
| | Thrombosis | 1 | 2023 | 393 | 0.040 |
Why?
| | DNA, Viral | 1 | 2021 | 361 | 0.040 |
Why?
| | Nicotine | 1 | 2021 | 331 | 0.040 |
Why?
| | Genotype | 1 | 2004 | 1837 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 645 | 0.040 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1327 | 0.040 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 276 | 0.040 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2000 | 232 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2011 | 2847 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1496 | 0.030 |
Why?
| | Asialoglycoproteins | 1 | 1997 | 2 | 0.030 |
Why?
| | Fetuins | 1 | 1997 | 3 | 0.030 |
Why?
| | Cytidine Monophosphate N-Acetylneuraminic Acid | 1 | 1997 | 3 | 0.030 |
Why?
| | MicroRNAs | 1 | 2024 | 699 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2000 | 251 | 0.030 |
Why?
| | Nervous System | 1 | 1998 | 70 | 0.030 |
Why?
| | alpha-Fetoproteins | 1 | 1997 | 40 | 0.030 |
Why?
| | Protein Binding | 1 | 2004 | 2261 | 0.030 |
Why?
| | Homozygote | 1 | 2017 | 201 | 0.030 |
Why?
| | Gene Dosage | 1 | 2017 | 148 | 0.030 |
Why?
| | Tretinoin | 1 | 1998 | 124 | 0.030 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2017 | 42 | 0.030 |
Why?
| | Heterozygote | 1 | 2017 | 315 | 0.030 |
Why?
| | Carbohydrate Conformation | 1 | 1996 | 15 | 0.030 |
Why?
| | Glycoproteins | 1 | 1998 | 357 | 0.030 |
Why?
| | Oligosaccharides | 1 | 1996 | 59 | 0.030 |
Why?
| | Parietal Lobe | 1 | 1996 | 60 | 0.030 |
Why?
| | Glutathione Reductase | 1 | 2015 | 25 | 0.030 |
Why?
| | Peroxiredoxins | 1 | 2015 | 26 | 0.030 |
Why?
| | Substrate Specificity | 1 | 1996 | 379 | 0.030 |
Why?
| | Brain Stem | 1 | 1996 | 96 | 0.030 |
Why?
| | Glutathione Transferase | 1 | 2015 | 99 | 0.030 |
Why?
| | Fetus | 1 | 2000 | 800 | 0.030 |
Why?
| | Adolescent | 2 | 2025 | 22233 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 1998 | 280 | 0.030 |
Why?
| | Acetylation | 1 | 2015 | 245 | 0.030 |
Why?
| | Aldehydes | 1 | 2015 | 144 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2015 | 210 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 573 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2017 | 537 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 743 | 0.030 |
Why?
| | Cerebellum | 1 | 1996 | 222 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 3556 | 0.020 |
Why?
| | Glutathione | 1 | 2015 | 379 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2017 | 884 | 0.020 |
Why?
| | Cell Differentiation | 2 | 1998 | 2045 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 349 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2017 | 2182 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 1995 | 443 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 524 | 0.020 |
Why?
| | Risk Factors | 1 | 2026 | 10623 | 0.020 |
Why?
| | SEC Translocation Channels | 1 | 2011 | 10 | 0.020 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 1 | 2011 | 93 | 0.020 |
Why?
| | Amino Acids | 1 | 2015 | 519 | 0.020 |
Why?
| | Lung | 1 | 2024 | 4143 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 379 | 0.020 |
Why?
| | Protein Stability | 1 | 2011 | 177 | 0.020 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2011 | 192 | 0.020 |
Why?
| | Child, Preschool | 1 | 2025 | 11631 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2011 | 342 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5761 | 0.020 |
Why?
| | HeLa Cells | 1 | 2011 | 653 | 0.020 |
Why?
| | Protein Transport | 1 | 2011 | 445 | 0.020 |
Why?
| | Qualitative Research | 1 | 2017 | 1626 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 645 | 0.020 |
Why?
| | Young Adult | 1 | 2025 | 13914 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 11459 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1255 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 1998 | 2220 | 0.020 |
Why?
| | Child | 1 | 2025 | 22441 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1504 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2022 | 16755 | 0.010 |
Why?
| | In Situ Nick-End Labeling | 1 | 2003 | 123 | 0.010 |
Why?
| | Chick Embryo | 1 | 2003 | 134 | 0.010 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2003 | 73 | 0.010 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2003 | 81 | 0.010 |
Why?
| | Chemokine CXCL12 | 1 | 2003 | 89 | 0.010 |
Why?
| | Nerve Growth Factors | 1 | 2003 | 78 | 0.010 |
Why?
| | Receptors, CXCR4 | 1 | 2003 | 91 | 0.010 |
Why?
| | Infant | 1 | 2017 | 9886 | 0.010 |
Why?
| | Cell Count | 1 | 2003 | 324 | 0.010 |
Why?
| | Cyclic AMP | 1 | 2003 | 209 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 126 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 298 | 0.010 |
Why?
| | Apelin Receptors | 1 | 2000 | 4 | 0.010 |
Why?
| | Dopamine D2 Receptor Antagonists | 1 | 2000 | 5 | 0.010 |
Why?
| | Apelin | 1 | 2000 | 10 | 0.010 |
Why?
| | Adipokines | 1 | 2000 | 58 | 0.010 |
Why?
| | Receptors, Virus | 1 | 2000 | 96 | 0.010 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2000 | 92 | 0.010 |
Why?
| | Cell Survival | 1 | 2003 | 1110 | 0.010 |
Why?
| | Primates | 1 | 2000 | 132 | 0.010 |
Why?
| | Swainsonine | 1 | 1999 | 1 | 0.010 |
Why?
| | 1-Deoxynojirimycin | 1 | 1999 | 1 | 0.010 |
Why?
| | Mannosidases | 1 | 1999 | 4 | 0.010 |
Why?
| | Neuraminidase | 1 | 1999 | 25 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1999 | 328 | 0.010 |
Why?
| | Phosphorylation | 1 | 2003 | 1761 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 952 | 0.010 |
Why?
| | Biological Transport | 1 | 1999 | 412 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2000 | 580 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2000 | 1270 | 0.010 |
Why?
| | Solubility | 1 | 1998 | 239 | 0.010 |
Why?
| | Blotting, Western | 1 | 1999 | 1207 | 0.010 |
Why?
| | Pituitary Neoplasms | 1 | 1999 | 191 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2000 | 750 | 0.010 |
Why?
| | HIV-1 | 1 | 2000 | 904 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2000 | 1522 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2000 | 2041 | 0.010 |
Why?
|
|
Coughlan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|